Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Incyte's (INCY) CEO Hervé Hoppenot on Q4 2021 Results - Earnings Call Transcript

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2021 Fourth Quarter and Year-end Financial Results and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

Adagio Therapeutics

Allakos Inc

Alnylam Pharmaceuticals

argenx

BridgeBio Pharma Inc

Bicycle Therapeutics Plc - ADR

BioMarin Pharmaceutical

Denali Therapeutics

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

SAGE Therapeutics

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.

Incyte (INCY) to Report Q4 Earnings: What's in the Offing?

BioLife Solutions

Seagen

Try your hand at morphing science and business for a great investment opportunity in biotech.

Best Biotech Stocks to Invest in Now

Eli Lilly

INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of the U.S. atopic dermatitis supplemental new drug application (sNDA). Lupus program update Based on top-line efficacy results from two pivotal Phase 3 trials (SLE-BRAVE-I and II), Lilly has decided to discontinue the Phase 3 development program for OLUMIANT in lupus.

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

Incyte Corporation is withdrawing the New Drug Application for parsaclisib in relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL).

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Provides Update on Parsaclisib and MCLA-145

Incyte Provides Update on Parsaclisib and MCLA-145

Incyte has recorded five years of substantial growth fueled by an expanding portfolio and commercial performance. I believe that Incyte's growth narrative will remain intact beyond 2022. Jakafi is approaching a patent cliff, but the company has numerous internal and external programs at various stages of development that can bolster the long-term bull thesis.

Incyte: Still Has Room To Grow

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Fourth Quarter and Year-End 2021 Financial Results

Incyte to Report Fourth Quarter and Year-End 2021 Financial Results

The company is gradually moving away from the concentration of revenue on sales of Jakafi. The biggest revenue driver is the start of Opzelura's sales.

Incyte: The Right Time To Buy The Stock

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) supplemental marketing application seeking approval for ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor for vitiligo.  Under the Priority Review, the application covers adolescents and adults (over 12 years) with vitiligo, a chronic autoimmune disease characterized by skin depigmentation.

Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo

Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo

Morphosys AG - ADR

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2 BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / December 11, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi(R)) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These treatments include polatuzumab vedotin plus bendamustine and rituximab (Pola-BR), rituximab plus lenalidomide (R2), and CD19 chimeric antigen receptor T-cell (CAR-T) therapies.

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

BOSTON & WILMINGTON, Del.--(BUSINESS WIRE)--MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (NASDAQ:INCY) today announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi®) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These treatments include polatuzumab vedotin plus bendamustine and ritu

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH21--Incyte Announces Updated Data Showing Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Down 2.7% Since Last Earnings Report?

Incyte Corporation runs a biopharmaceutical business with several commercialized products. The company does not only envisage that Jakafi may bring close to $3 billion in peak sales. Monjuvi is also expected to report $500-$750 million in sales.

Incyte's Increase In Jakafi's Sales Guidance Implies 29% Upside In The Valuation

INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously published findings. Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeting taking place November 3-9, 2021.

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

Amgen

Biogen

Gilead Sciences

Regeneron Pharmaceuticals

Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.

5 Buy-Rated Biotech Stocks to Bolster Your Portfolio

HOUSTON and SHANGHAI, Nov. 4, 2021 /PRNewswire/ -- Cellenkos ®  Inc. ("Cellenkos"), a biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders, today announced the close of $15 million Series A financing led by BVCF Management Ltd ("BVCF"). Proceeds from this financing will be used to further its development on the Treg cell therapy platform to address high unmet needs in autoimmune and inflammatory disorders.

Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH21--More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition.

More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

Incyte Corporation (INCY) CEO Herve Hoppenot on Q3 2021 results - Earnings Call Transcript

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow

Incyte (INCY) delivered earnings and revenue surprises of 55.26% and 8.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Incyte Stock (INCY)